Your Article Summary
See Latest ArticlesActive Biotech Completes Patient Enrollment to ANYARA Phase III Clinical Trial
Active Biotech, 06/02/09
This pivotal Phase III study evaluates the efficacy and safety of ANYARA in combination with interferon-alfa compared to interferon-alfa alone, in patients with advanced renal cell cancer. The primary clinical efficacy parameter is overall survival. Final survival data for ANYARA will be analyzed after 384 events and the current estimate is that these will be presented by the end of 2010/beginning of 2011.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety First in Biotech Development
BioPharm, 12/03/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Complete Genomics and GATC Biotech Collaborate on Human Genome Sequencing Projects
b3c newswire, 12/02/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09